Company Description
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers.
The company was incorporated in 2014 and is based in Copenhagen, Denmark.
| Country | Denmark |
| Founded | 2014 |
| IPO Date | Nov 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Dr. Mai-Britt Zocca Ph.D. |
Contact Details
Address: Ole Maaloes Veh 3 Copenhagen, G7 2200 Denmark | |
| Phone | 4570702980 |
| Website | iobiotech.com |
Stock Details
| Ticker Symbol | IOBT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001865494 |
| CUSIP Number | 449778109 |
| ISIN Number | US4497781090 |
| Employer ID | 87-0909276 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mai-Britt Zocca Ph.D. | Founder, President, Chief Executive Officer, Principal Financial Officer and Director |
| Amy B. Sullivan M.B.A. | Chief Financial Officer |
| Prof. Inge Marie Svane M.D., Ph.D. | Founder and Clinical Advisor |
| Prof. Mads Hald Andersen M.D., Ph.D. | Founder and Scientific Advisor |
| Anders Ljungqvist | Founder |
| Prof. Per Thor Straten | Founder |
| Brian Burkavage CPA | Chief Accounting Officer |
| Eric Faulkner M.B.A. | Chief Technical Officer |
| Devin Whittemore Smith | Secretary, General Counsel and Chief Compliance Officer |
| Daniel G. Mannix Ph.D. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 22, 2024 | 10-K/A | [Amend] Annual report |
| Mar 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2024 | 10-K | Annual Report |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |